## Jason Weatherald

## List of Publications by Citations

Source: https://exaly.com/author-pdf/2689374/jason-weatherald-publications-by-citations.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

77
papers

1,323
citations

18
h-index
g-index

102
ext. papers

2,996
ext. citations

5,7
avg, IF
L-index

#	Paper	IF	Citations
77	Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , <b>2017</b> , 50,	13.6	298
76	Prognostic Value of Follow-Up Hemodynamic Variables After Initial Management in Pulmonary Arterial Hypertension. <i>Circulation</i> , <b>2018</b> , 137, 693-704	16.7	92
75	Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension. <i>European Respiratory Journal</i> , <b>2017</b> , 50,	13.6	69
74	Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study. <i>European Respiratory Journal</i> , <b>2017</b> , 50,	13.6	62
73	Cardiopulmonary Exercise Testing in Pulmonary Hypertension. <i>Annals of the American Thoracic Society</i> , <b>2017</b> , 14, S84-S92	4.7	50
72	Ventilatory response to exercise in cardiopulmonary disease: the role of chemosensitivity and dead space. <i>European Respiratory Journal</i> , <b>2018</b> , 51,	13.6	45
71	Ion Channels in Pulmonary Hypertension: A Therapeutic Interest?. <i>International Journal of Molecular Sciences</i> , <b>2018</b> , 19,	6.3	45
70	Haemodynamics and serial risk assessment in systemic sclerosis associated pulmonary arterial hypertension. <i>European Respiratory Journal</i> , <b>2018</b> , 52,	13.6	37
69	Predictors of survival in patients with not-operated chronic thromboembolic pulmonary hypertension. <i>Journal of Heart and Lung Transplantation</i> , <b>2019</b> , 38, 833-842	5.8	32
68	Pulmonary arterial hypertension induced by tyrosine kinase inhibitors. <i>Current Opinion in Pulmonary Medicine</i> , <b>2017</b> , 23, 392-397	3	31
67	Awake prone positioning for COVID-19 hypoxemic respiratory failure: A rapid review. <i>Journal of Critical Care</i> , <b>2021</b> , 61, 63-70	4	29
66	Acute decompensated pulmonary hypertension. European Respiratory Review, 2017, 26,	9.8	28
65	The Low-Risk Profile in Pulmonary Arterial Hypertension. Time for a Paradigm Shift to Goal-oriented Clinical Trial Endpoints?. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2018</b> , 197, 860-868	10.2	27
64	Dead-space ventilation is linked to exercise capacity and survival in distal chronic thromboembolic pulmonary hypertension. <i>Journal of Heart and Lung Transplantation</i> , <b>2017</b> , 36, 1234-1242	5.8	25
63	Tolerability and safety of awake prone positioning COVID-19 patients with severe hypoxemic respiratory failure. <i>Canadian Journal of Anaesthesia</i> , <b>2021</b> , 68, 64-70	3	25
62	Clinical phenotypes and survival of pre-capillary pulmonary hypertension in systemic sclerosis. <i>PLoS ONE</i> , <b>2018</b> , 13, e0197112	3.7	24
61	Association Between BMI and Obesity With Survival in Pulmonary Arterial Hypertension. <i>Chest</i> , <b>2018</b> , 154, 872-881	5.3	22

## (2018-2019)

60	Screening for pulmonary arterial hypertension in systemic sclerosis. <i>European Respiratory Review</i> , <b>2019</b> , 28,	9.8	21	
59	Heritable pulmonary hypertension: from bench to bedside. European Respiratory Review, 2017, 26,	9.8	17	
58	Poor Subpleural Perfusion Predicts Failure After Balloon Pulmonary Angioplasty for Nonoperable Chronic Thromboembolic Pulmonary Hypertension. <i>Chest</i> , <b>2018</b> , 154, 521-531	5.3	17	
57	A Prospective Evaluation of the Diagnostic Accuracy of the Physical Examination for Pulmonary Hypertension. <i>Chest</i> , <b>2019</b> , 155, 982-990	5.3	16	
56	Intensity and quality of exertional dyspnoea in patients with stable pulmonary hypertension. <i>European Respiratory Journal</i> , <b>2020</b> , 55,	13.6	16	
55	Factors predicting outcome after pulmonary endarterectomy. <i>PLoS ONE</i> , <b>2018</b> , 13, e0198198	3.7	16	
54	Chronic blood exchange transfusions in the management of pre-capillary pulmonary hypertension complicating sickle cell disease. <i>European Respiratory Journal</i> , <b>2018</b> , 52,	13.6	15	
53	Medical Management of Pulmonary Hypertension with Unclear and/or Multifactorial Mechanisms (Group 5): Is There a Role for Pulmonary Arterial Hypertension Medications?. <i>Current Hypertension Reports</i> , <b>2017</b> , 19, 86	4.7	14	
52	Risk assessment in pulmonary arterial hypertension. European Respiratory Journal, 2018, 51,	13.6	14	
51	Precision medicine and personalising therapy in pulmonary hypertension: seeing the light from the dawn of a new era. <i>European Respiratory Review</i> , <b>2018</b> , 27,	9.8	13	
50	Association between Initial Treatment Strategy and Long-Term Survival in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2021</b> , 204, 842-854	10.2	13	
49	Golden Ratio and the Proportionality Between Pulmonary Pressure Components in Pulmonary Arterial Hypertension. <i>Chest</i> , <b>2019</b> , 155, 991-998	5.3	12	
48	Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors. <i>European Respiratory Journal</i> , <b>2020</b> , 56,	13.6	11	
47	Characterization of Right Ventricular Deformation in Pulmonary Arterial Hypertension Using Three-Dimensional Principal Strain Analysis. <i>Journal of the American Society of Echocardiography</i> , <b>2019</b> , 32, 385-393	5.8	11	
46	Pulmonary arterial hypertension secondary to adult-onset Still's disease: Response to cyclosporine and sildenafil over 15 years of follow-up. <i>Respiratory Medicine Case Reports</i> , <b>2016</b> , 19, 27-30	1.2	10	
45	Pulmonary capillary haemangiomatosis: a distinct entity?. European Respiratory Review, 2020, 29,	9.8	9	
44	Seeing the Forest for the (Arterial) Tree: Vascular Pruning and the Chronic Obstructive Pulmonary Disease Pulmonary Vascular Phenotype. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2019</b> , 200, 406-408	10.2	8	
43	Risk stratification in pulmonary arterial hypertension. <i>Current Opinion in Pulmonary Medicine</i> , <b>2018</b> , 24, 407-415	3	8	

42	Clinical and Hemodynamic Correlates of Pulmonary Arterial Stiffness in Incident, Untreated Patients With Idiopathic Pulmonary Arterial Hypertension. <i>Chest</i> , <b>2018</b> , 154, 882-892	5.3	7
41	Pulmonary Hypertension and Exercise. <i>Clinics in Chest Medicine</i> , <b>2019</b> , 40, 459-469	5.3	7
40	Delivering pulmonary rehabilitation during the COVID-19 pandemic: A Canadian Thoracic Society position statement. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , <b>2020</b> , 4, 232-235	0.6	6
39	Echocardiography-Derived Stroke Volume Index Is Associated With Adverse In-Hospital Outcomes in Intermediate-Risk Acute Pulmonary Embolism: A Retrospective Cohort Study. <i>Chest</i> , <b>2020</b> , 158, 1132-	151342	6
38	Mortality trends in pulmonary arterial hypertension in canada: a temporal analysis of survival per ESC/ERS Guideline Era. <i>European Respiratory Journal</i> , <b>2021</b> ,	13.6	6
37	Gas Exchange and Ventilatory Efficiency During Exercise in Pulmonary Vascular Diseases. <i>Archivos De Bronconeumologia</i> , <b>2020</b> , 56, 578-585	0.7	6
36	Pulmonary Vascular Disease and Cardiopulmonary Exercise Testing. <i>Frontiers in Physiology</i> , <b>2020</b> , 11, 964	4.6	6
35	Pseudocyanosis: drug-induced skin hyperpigmentation can mimic cyanosis. <i>American Journal of Medicine</i> , <b>2008</b> , 121, 385-6	2.4	5
34	Survival Improved in Patients Aged 170 Years With Systemic Sclerosis-Associated Pulmonary Arterial Hypertension During the Period 2006 to 2017 in France. <i>Chest</i> , <b>2020</b> , 157, 945-954	5.3	5
33	Dasatinib-Induced Pulmonary Arterial Hypertension. Canadian Journal of Cardiology, <b>2019</b> , 35, 1604.e1-	1 <b>6.8</b> 4.e	·3 <sub>4</sub>
32	External validation of a refined 4-strata risk assessment score from the French pulmonary hypertension Registry. <i>European Respiratory Journal</i> , <b>2021</b> ,	13.6	4
31	Ventilatory efficiency in pulmonary vascular diseases. European Respiratory Review, 2021, 30,	9.8	4
30	Response to the article "Sorafenib as a potential strategy for refractory pulmonary arterial hypertension". <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2017</b> , 45, 11-12	3.5	3
29	Trends in diagnosis and management of idiopathic pulmonary fibrosis in Canada. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , <b>2017</b> , 1, 71-76	0.6	3
28	Canadian Thoracic Society position statement on rehabilitation for COVID-19 and implications for pulmonary rehabilitation. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> ,1-5	0.6	3
27	Tyrosine Kinase InhibitorInduced Pulmonary Arterial Hypertension. <i>Advances in Pulmonary Hypertension</i> , <b>2018</b> , 17, 69-74	0.5	3
26	Impact of saline loading at cardiac catheterization on the classification and management of patients evaluated for pulmonary hypertension. <i>International Journal of Cardiology</i> , <b>2020</b> , 306, 181-186	3.2	3
25	Chronic thromboembolic pulmonary hypertension and totally implantable central venous access	13.6	

## (2018-2022)

24	The effectiveness of pulmonary rehabilitation for Post-COVID symptoms: A rapid review of the literature <i>Respiratory Medicine</i> , <b>2022</b> , 195, 106782	4.6	3
23	Are indexed values better for defining exercise pulmonary hypertension?. <i>European Respiratory Journal</i> , <b>2017</b> , 50,	13.6	2
22	Patterns of cardiopulmonary response to exercise in pulmonary vascular diseases160-174		2
21	Position statement from the Canadian Thoracic Society (CTS) on clinical triage thresholds in respiratory disease patients in the event of a major surge during the COVID-19 pandemic. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , <b>2020</b> , 4, 214-225	0.6	2
20	Rapid prediction of adverse outcomes for acute normotensive pulmonary embolism: derivation of the Calgary Acute Pulmonary Embolism score. <i>ERJ Open Research</i> , <b>2021</b> , 7,	3.5	2
19	Pulmonary Embolism: The Value of the Angiographic Diagnosis. <i>Canadian Journal of Cardiology</i> , <b>2019</b> , 35, 940.e1-940.e3	3.8	1
18	Bronchoscopic resection of a central typical carcinoid tumour. <i>Canadian Respiratory Journal</i> , <b>2015</b> , 22, 16	2.1	1
17	Pulmonary Hypertension Associated with Chronic Lung Diseases: Treatment Considerations. <i>Respiratory Medicine</i> , <b>2020</b> , 79-96	0.2	1
16	ERS International Congress, Madrid, 2019: highlights from the Pulmonary Vascular Diseases Assembly. <i>ERJ Open Research</i> , <b>2020</b> , 6,	3.5	1
15	The isobaric pulmonary arterial compliance in pulmonary hypertension. ERJ Open Research, 2021, 7,	3.5	1
14	Chronic fatigue and post-exertional malaise in people living with long COVID		1
13	Klippel-Trenaunay syndrome as a rare cause of chronic thromboemboembolic pulmonary hypertension. <i>Respiratory Medicine and Research</i> , <b>2019</b> , 76, 48-53	1.4	1
12	Awake prone positioning in COVID-19: is tummy time ready for prime time?. <i>Lancet Respiratory Medicine,the</i> , <b>2021</b> , 9, 1347-1349	35.1	1
11	Gas Exchange and Ventilatory Efficiency During Exercise in Pulmonary Vascular Diseases. <i>Archivos De Bronconeumologia</i> , <b>2020</b> , 56, 578-585	0.7	O
10	Pulmonary Vascular Resistance in Pulmonary Arterial Hypertension: La Pille de Raistance?. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2021</b> , 203, 524-525	10.2	O
9	Association between Leflunomide and Pulmonary Hypertension. <i>Annals of the American Thoracic Society</i> , <b>2021</b> , 18, 1306-1315	4.7	O
8	Response. <i>Chest</i> , <b>2019</b> , 156, 630-631	5.3	
7	Complications of pulmonary artery aneurysms in pulmonary arterial hypertension. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , <b>2018</b> , 2, 173-177	0.6	_

6	case series and literature review. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine,1-6	0.6
5	Pulmonary vascular diseases. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , <b>2021</b> , 5, 108-113	0.6
4	Does community size or commute time affect severity of illness at diagnosis or quality of care in a centralized care model of pulmonary hypertension?. <i>International Journal of Cardiology</i> , <b>2021</b> , 332, 175-	-181
3	Management of Pulmonary Hypertension Due to Chronic Lung Disease. <i>Methodist DeBakey Cardiovascular Journal</i> , <b>2021</b> , 17, 124-133	2.1
2	Pulmonary vascular diseases. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , <b>2020</b> , 4, S2-S5	0.6
1	Palliative Care in Pulmonary Arterial Hypertension. <i>Respiratory Medicine</i> , <b>2021</b> , 255-279	0.2